

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/534,772
		Filing Date	(Int'l.) November 13, 2003
		First Named Inventor	Stephen TOMLINSON
		Art Unit	1644
		Examiner Name	S. Wen
Sheet	1	of	2
		Attorney Docket Number	577712000200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2007/0224197-A1	09-27-2007	Chen et al.	
	2.	US-5,260,203-A	11-09-1993	Ladner et al.	
	3.	US-7,759,304-B2	07-20-2010	Gilkeson et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	4.	JP-5-507197-A	10-21-1993	The Johns Hopkins University	Translation of Abstract Only
	5.	JP-9-502985-A	03-25-1997	Ko et al.	Translation of Abstract Only
	6.	WO-2007/035857-A2, A3	03-29-2007	Palingen, Inc.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	7.	HARLOW, E. et al. eds. (1988). "Proteolytic Fragments of Antibodies," in Chapter 15 in <u>Antibodies, A Laboratory Manual</u> , Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, pp. 626-629.			
	8.	KUBY, J. (1994). "Antigens," in Chapter 4 in <u>Immunology</u> , W.H. Freeman and Company: New York, 2:85-96.			
	9.	MOLD, C. et al. (June 1, 1988). "Activation of the Alternative Complement Pathway by EBV and the Viral Envelope Glycoprotein, gp350," <u>J. Immunology</u> 140(11):3867-3874.			
	10.	NGO, J.T. et al. (1994). "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," Chapter 14 in <u>The Protein Folding and Tertiary Structure Prediction</u> , Merz, K. et al. eds., Birkhäuser Publishing: Boston, MA, pp. 491-495.			
	11.	PIATESI, A. et al. (2004). "Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diels-Alder Activity," <u>ChemBioChem</u> 5:460-466.			
	12.	RUDIKOFF, S. et al. (March 1982). "Single Amino Acid Substitution Altering Antigen-Binding Specificity," <u>Proc. Natl. Acad. Sci.</u> 79:1979-1983.			
	13.	STYER, L. et al. (1998). "Levels of Structure in Protein Architecture," in Chapter 2 in <u>Biochemistry</u> , W.H. Freeman and Company: New York, 3:31-33.			

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/534,772
				Filing Date	(Int'l.) November 13, 2003
				First Named Inventor	Stephen TOMLINSON
				Art Unit	1644
				Examiner Name	S. Wen
Sheet	2	of	2	Attorney Docket Number	577712000200

	14.	ZHU, Z. et al. (1999). "Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor," <i>Investigational New Drugs</i> 17:195-212.	
--	-----	---	--

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.